Sponsored Content
Intercell Continues Development of Vaccines
The Austrian pharmaceutical company announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections.
Intercell Continues Development of Vaccines / Picture: © Vindobona.org
Intercell today announced first data from a Phase I clinical trial with the company's vaccine candidate IC84 to prevent disease caused by the bacterium Clostridium difficile (C. difficile). The pathogen is one of the main causes of nosocomial diarrhea.
Intercell's vaccine candidate is a recombinant protein vaccine consisting of two truncated toxins A and B from C. difficile. The…
or Log In
Fast News Search